SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-23-007393
Filing Date
2023-05-01
Accepted
2023-05-01 07:35:33
Documents
13
Period of Report
2023-05-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tgtx-20230501x8k.htm   iXBRL 8-K 33502
2 EX-99.1 tgtx-20230501xex99d1.htm EX-99.1 111567
  Complete submission text file 0001558370-23-007393.txt   282007

Data Files

Seq Description Document Type Size
3 EX-101.SCH tgtx-20230501.xsd EX-101.SCH 3440
4 EX-101.LAB tgtx-20230501_lab.xml EX-101.LAB 16023
5 EX-101.PRE tgtx-20230501_pre.xml EX-101.PRE 11021
7 EXTRACTED XBRL INSTANCE DOCUMENT tgtx-20230501x8k_htm.xml XML 4789
Mailing Address 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK NY 10014
Business Address 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK NY 10014 (212) 554-4484
TG THERAPEUTICS, INC. (Filer) CIK: 0001001316 (see all company filings)

IRS No.: 363898269 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32639 | Film No.: 23870032
SIC: 2834 Pharmaceutical Preparations